The Burden of Irritable Bowel Syndrome and Functional Dyspepsia in Poland: A Cross- Sectional Study from West Pomeranian Voivodship DOI Creative Commons
Patrycja Krynicka, Mariusz Kaczmarczyk, Karolina Skonieczna‐Żydecka

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 22, 2024

Abstract Background Functional gastrointestinal disorders (FGIDs), now known as of gut-brain interaction (DGBIs), such Irritable Bowel Syndrome (IBS) and Dyspepsia (FD), significantly impact global health, reducing quality life burdening healthcare systems. This study addresses the epidemiological gap in Poland, focusing on West Pomeranian Voivodeship. Methods We conducted a cross-sectional 2070 Caucasian patients (58.2% female, mean age 57.5 ± 15.1 years) undergoing endoscopic examinations at Medical University from 2021 to 2023. Data were collected using Rome IV diagnostic questionnaires correlated with gastroduodenoscopy colonoscopy findings. Exclusion criteria under 18, pregnancy, Crohn’s disease, ulcerative colitis, severe comorbidities, cancer, immunosuppressive therapy, ileostomy/colostomy, incomplete questionnaires, or lack consent. Results Using criteria, IBS was diagnosed 436 participants (21.1%) FD 248 (12.0%). Post-endoscopic evaluation revised diagnoses 184 individuals (8.9%). Females had higher prevalence (OR 1.64 1.61, respectively). No significant association found between BMI increased risk FD. Hypertension diabetes 35.1% 13.0%, respectively. Individuals history COVID-19 developing 1.47, P = 0.050). Conclusions Our provides crucial data emphasizing importance evaluations. findings highlight need for regional studies understand local DGBI prevalence, aiding targeted strategies.

Language: Английский

The burden of irritable bowel syndrome and functional dyspepsia in Poland: a cross-sectional study from West Pomeranian Voivodship DOI Creative Commons
Patrycja Krynicka, Mariusz Kaczmarczyk, Karolina Skonieczna‐Żydecka

et al.

BMC Gastroenterology, Journal Year: 2025, Volume and Issue: 25(1)

Published: Jan. 9, 2025

Language: Английский

Citations

1
Prescription of commonly used drugs in patients with functional bowel disorders. A cross-sectional comparison with the general population DOI Creative Commons

Alice Sandberg‐Janzon,

Pontus Karling

Scandinavian Journal of Gastroenterology, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 9

Published: Jan. 25, 2025

Objectives Comorbidity with other conditions is common in functional bowel disorders. We aimed to investigate the prescription patterns of commonly used drugs patients irritable syndrome (IBS) and unspecific disorder, compared general population.

Language: Английский

Citations

1
Impact of Microbiota on Irritable Bowel Syndrome Pathogenesis and Management: A Narrative Review DOI Creative Commons

Mhd Bashir Almonajjed,

Mahdi Wardeh,

Abdallah Atlagh

et al.

Medicina, Journal Year: 2025, Volume and Issue: 61(1), P. 109 - 109

Published: Jan. 13, 2025

Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder, affecting 3–5% of the global population and significantly impacting patients’ quality life healthcare resources. Alongside physical symptoms such as abdominal pain altered habits, many individuals experience psychological comorbidities, including anxiety depression. Recent research has highlighted critical role gut microbiota in IBS, with dysbiosis, characterized by an imbalance microbial diversity, frequently observed patients. The gut–brain axis, bidirectional communication network between central nervous system, plays development IBS symptoms. Although interventions probiotics, prebiotics, synbiotics, fecal transplantation (FMT) have demonstrated potential modulating alleviating symptoms, their efficacy remains area ongoing investigation. This review examines interactions microbiota, immune brain, emphasizing need for personalized therapeutic strategies. Future should aim to identify reliable microbiota-based biomarkers refine microbiome-targeted therapies enhance patient outcomes.

Language: Английский

Citations

0
Irritable bowel syndrome, the gut microbiome, and diet DOI

Rosa Lu Yu,

H. Christian Weber

Current Opinion in Endocrinology Diabetes and Obesity, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 19, 2025

Purpose of review To provide an update recent studies exploring the role gut microbiota and diet in pathogenesis treatment irritable bowel syndrome (IBS). Recent findings The human microbiome has been recognized as important, active source signaling molecules that explain part disorder brain interaction (DGBI) IBS. Subsequent changes metabolome such production short-chain fatty acids (SCFA) serotonin are associated with IBS symptoms. Dietary components important triggers symptoms a low fermentable oligo-, di-, monosaccharides, polyols (FODMAPs) shown effective safe, even when used long-term. Fecal transplantation (FMT) not sustained symptom reduction controlled clinical trials. Summary This elucidates developments it relates to trial results targeting dietary interventions. is metabolically affects bi-directional gut-brain axis.

Language: Английский

Citations

0
Functional Foods and Nutraceuticals in Irritable Bowel Syndrome DOI Open Access
Giovanni Marasco, Cesare Cremon, Daniele Salvi

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(6), P. 1830 - 1830

Published: March 8, 2025

Irritable bowel syndrome (IBS) is a common disorder of gut–brain interaction, with multifactorial pathophysiology involving axis dysregulation, visceral hypersensitivity, microbiota imbalance, and immune dysfunction. Traditional IBS management emphasizes dietary modifications pharmacologic therapies. However, increasing attention has been directed toward functional foods, nutraceuticals, herbal remedies due to their potential target pathophysiological mechanisms favorable safety profiles. This clinical review explores the role these adjunctive therapies, evaluating evidence from preclinical studies. Functional foods such as kiwifruit, prunes, rye bread demonstrate benefits in habit regulation through fiber content modulation. Nutraceuticals like peppermint oil, palmitoylethanolamide, mixtures exhibit anti-inflammatory, antispasmodic, analgesic effects. Prebiotics provide substrate-driven changes, although dosage key, given fermentative properties, when used at high dosages, they can exacerbate symptoms some individuals. Probiotics postbiotics offer microbiota-based interventions promising symptom relief subtypes, factors for personalized treatment still need be further elucidated. These strategies highlight paradigm shift management, integrating diet-based therapies evolving nutraceutical options improve patient outcomes. Despite findings, challenges standardizing definitions, mechanisms, profiles remain. Rigorous, large-scale trials validate therapeutic are needed, enhance compounds an individualized approach.

Language: Английский

Citations

0
Trasplante de microbiota fecal mediante colonoscopia para el manejo del síndrome de intestino irritable refractario: resultados preliminares DOI Creative Commons
Christian von Mühlenbrock, Paulina Núñez, K. Herrera

et al.

Revista de Gastroenterología de México, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Citations

0
The IBS and SIBO dilemma: Here we go again DOI
Giovanni Marasco, Edoardo Savarino, Giovanni Barbara

et al.

Digestive and Liver Disease, Journal Year: 2024, Volume and Issue: 56(12), P. 2025 - 2026

Published: Aug. 31, 2024

Language: Английский

Citations

2
Insights into Probiotic Prescription among Gastroenterologists and Other Healthcare Professionals: Evidence from an Italian Survey DOI Open Access
Giovanni Marasco,

Angelo Bruni,

Olga Maria Nardone

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(16), P. 4749 - 4749

Published: Aug. 13, 2024

Background: Probiotics, which are live microorganisms that provide health benefits, have been extensively studied for their various clinical applications. However, despite potential, high-quality data supporting use in several gastrointestinal diseases often lacking, and prescription behaviors can widely differ. This study aimed to assess different probiotics knowledge prescriptions among Italian gastroenterologists healthcare professionals (HPs). Methods: A web-based electronic survey was distributed all participants at the National Meeting of Young Gastroenterologist Endoscopist Association (AGGEI) held 2023. The investigated probiotic practices conditions, such as acute diarrhea, irritable bowel syndrome, inflammatory disease, diverticular disease. Results: Among 200 participants, 142 completed survey, whom 59 were 83 HPs (surgeons, nutrition biologists, other physicians). Significant differences observed treatment diarrhea H. pylori. Both groups prescribed monthly cycles patients with IBS, although majority multistrain formulations. Gastroenterologists more likely prescribe cyclic courses while tended continue therapy by changing strain case inefficacy. For ulcerative colitis, but shorter durations. In Crohn’s less Regarding SUDD, frequently, without a significant difference, similar rates preference Conclusions: highlights heterogeneous between HPs, aligned guidelines available scientific evidence. Hence, enhancing education is crucial. Further studies needed better understand probiotics’ role disorders through large-scale randomized controlled trials.

Language: Английский

Citations

0
The Burden of Irritable Bowel Syndrome and Functional Dyspepsia in Poland: A Cross- Sectional Study from West Pomeranian Voivodship DOI Creative Commons
Patrycja Krynicka, Mariusz Kaczmarczyk, Karolina Skonieczna‐Żydecka

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 22, 2024

Abstract Background Functional gastrointestinal disorders (FGIDs), now known as of gut-brain interaction (DGBIs), such Irritable Bowel Syndrome (IBS) and Dyspepsia (FD), significantly impact global health, reducing quality life burdening healthcare systems. This study addresses the epidemiological gap in Poland, focusing on West Pomeranian Voivodeship. Methods We conducted a cross-sectional 2070 Caucasian patients (58.2% female, mean age 57.5 ± 15.1 years) undergoing endoscopic examinations at Medical University from 2021 to 2023. Data were collected using Rome IV diagnostic questionnaires correlated with gastroduodenoscopy colonoscopy findings. Exclusion criteria under 18, pregnancy, Crohn’s disease, ulcerative colitis, severe comorbidities, cancer, immunosuppressive therapy, ileostomy/colostomy, incomplete questionnaires, or lack consent. Results Using criteria, IBS was diagnosed 436 participants (21.1%) FD 248 (12.0%). Post-endoscopic evaluation revised diagnoses 184 individuals (8.9%). Females had higher prevalence (OR 1.64 1.61, respectively). No significant association found between BMI increased risk FD. Hypertension diabetes 35.1% 13.0%, respectively. Individuals history COVID-19 developing 1.47, P = 0.050). Conclusions Our provides crucial data emphasizing importance evaluations. findings highlight need for regional studies understand local DGBI prevalence, aiding targeted strategies.

Language: Английский

Citations

0